Boehringer Ingelheim is to collaborate with UK biotech Autifony Therapeutics to develop an early-stage schizophrenia drug and other compounds. Although central nervous system diseases are a focus ...

Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the ...

Recognizing the potential to improve the treatment of diseases including schizophrenia, depression and impulsivity disorders, Boehringer Ingelheim is seeking opportunities to use its discovery and ...

Boehringer Ingelheim Human Pharma head Carinne Brouillon said ... agreement with Sosei Heptares for the development of a new class of therapies for all schizophrenia symptoms. Under the deal, the ...

The rise in research and development activities in schizophrenia treatment is driving market growth by fostering the development of innovative therapies, including novel antipsychotics and ...

Tokyo, Japan and Cambridge, UK, 23 October 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – is pleased to announce that it has won ...

No individual antipsychotic was associated with better cognitive outcomes than placebo in patients with schizophrenia spectrum disorders (SSD), according to a systematic review an ...

Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces that its ongoing ion channel research collaboration with Boehringer Ingelheim has advanced to the lead optimization s ...

HLTH 2024, scheduled for October 20-23 at the Venetian Expo Center in Las Vegas, will highlight new programming, a physicians roundtable, generative AI, the shifting landscapes of telemedicine ...

Boehringer Ingelheim is to collaborate with UK biotech Autifony Therapeutics to develop an early-stage schizophrenia drug and other compounds. Although central nervous system diseases are a focus ...

By Noah Weiland and Rebecca Robbins Hikma said it had reduced the cash portion of the offer as Boehringer Ingelheim’s generic drugs business in the U.S. had lower-than-expected sales.